RYTM — RHYTHM PHARMACEUTICALS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1649904 ·
Last close
$116.61
Market Cap
$8.08B
52W High
$122.20
52W Low
$74.50
ADV30
1,522,794
Next earnings
2026-11-03
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 92,128,000 | 79,962,000 | -39,270,000 | -41,369,000 | 443,132,000 | 39,981,000 | 241,589,000 |
| Jun 2026 | 71,255,000 | 62,324,000 | -48,552,000 | -49,298,000 | 437,266,000 | 65,614,000 | 219,965,000 |
| Mar 2026 | 60,112,000 | 52,955,000 | -52,361,000 | -55,639,000 | 442,316,000 | 62,137,000 | 204,700,000 |
| Dec 2025 | 57,253,000 | 52,451,000 | -47,063,000 | -47,505,000 | 480,196,000 | 54,301,000 | 210,170,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-81,788,000
Investing CF
$85,306,000
Financing CF
$-15,761,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.90
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,498,183,000
Inventory
$31,187,000
Receivables
$39,120,000
ST Investments
$280,963,000
EBIT TTM
$-174,010,000
Pretax Income TTM
$-192,243,000
Interest Exp TTM
$18,233,000
Analysts
17
Yahoo Snapshot (yfinance, live)
Total Revenue
$280,747,008
EBITDA
$-186,227,008
Free Cash Flow
$-17,757,876
Enterprise Value
$7,683,288,064
Total Cash
$320,944,000
Total Debt
$106,181,000
Shares Out
69,330,906
Trailing EPS
$-2.91
Book Value
$1.27
ROE
-78.0%
ROA
-24.6%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 189,757,000 | -192,016,000 | -196,539,000 | 480,196,000 | 210,170,000 | 270,026,000 | -115,675,000 |
| Dec 2024 | 130,126,000 | -265,503,000 | -260,602,000 | 392,273,000 | 227,724,000 | 164,549,000 | -113,879,000 |
| Dec 2023 | 77,428,000 | -184,357,000 | -184,678,000 | 332,745,000 | 162,986,000 | 169,759,000 | -136,157,000 |
| Dec 2022 | 23,638,000 | -179,157,000 | -181,119,000 | 382,481,000 | 118,219,000 | 264,262,000 | -173,428,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$239,918,000
NetIncome TTM
$-205,346,000
OpCashFlow TTM
—
Assets (Latest)
$437,266,000
Forward EPS
$-1.30
Max Pain — expiry 2027-01-15
max pain strike: $90.00 · spot: $119.04 · call oi: 1,755 · put oi: 351Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PTGX | Protagonist Therapeutics, Inc | $8.07B | $124.67 | — |
| CORT | CORCEPT THERAPEUTICS INC | $7.67B | $70.07 | — |
| PRAX | Praxis Precision Medicines, Inc. | $8.53B | $305.06 | — |
| SMMT | Summit Therapeutics Inc. | $8.53B | $10.67 | — |
| ALKS | Alkermes plc. | $7.64B | $45.45 | — |
News headlines (Yahoo Finance, 1h cache)
Rhythm Stock Is Up 32%. Is One Drug Enough?
2026-11-18 11:32 · Yahoo
Rhythm Pharmaceuticals Says Rare Obesity Drug Delivers Sustained Two-Year BMI Reductions
2026-11-17 15:11 · Yahoo
Rhythm Pharmaceuticals Announces Presentation of New Data at ObesityWeek® 2026
2026-11-16 21:00 · Yahoo
RYTM Stock Clocks Best Day In Nearly 16 Months On AstraZeneca $10B Bid Report
2026-11-04 22:20 · Yahoo
Rhythm Pharmaceuticals stock surges 28% on AstraZeneca bid report
2026-11-04 21:53 · Yahoo
Could Rhythm Pharmaceuticals (RYTM) Be Too Pricey After Recent Funding?
2026-11-04 18:16 · Yahoo
Rhythm Pharmaceuticals Stock In Focus After Earnings Beat And $750 Million Financing
2026-11-04 14:16 · Yahoo
Rhythm Pharmaceuticals Announces NICE Guidance for IMCIVREE® (Setmelanotide) Updated to Include Adults Living with Bardet-Biedl Syndrome
2026-11-04 13:00 · Yahoo
What Does Rhythm Pharmaceuticals (RYTM) Mean With A $750 Million Financing Deal?
2026-11-04 10:20 · Yahoo
Rhythm Pharmaceuticals (RYTM) Dropped, So What Is Behind The Fresh Attention?
2026-11-04 07:10 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.